Department of Surgery, Erasmus Medical Centre, 3015 CE Rotterdam, The Netherlands.
Cancer. 2010 Feb 15;116(4):830-6. doi: 10.1002/cncr.24809.
Adjuvant therapies for pancreatic and periampullary cancer reportedly achieve only a marginal survival benefit. In this randomized controlled trial, 120 patients with resected pancreatic or periampullary cancer received either adjuvant celiac axis infusion chemotherapy combined with radiotherapy (CAI/RT) or no adjuvant treatment. The objective of the study was to compare the quality of life (QoL) in patients who received CAI/RT after pancreatoduodenectomy with the QoL in patients who did not receive adjuvant treatment.
During and after CAI/RT, QoL was assessed using the European Organization for Research and Treatment of Cancer QoL Questionnaire C30 every 3 months during the first 24 months after randomization.
Eighty-six percent of patients (n = 103) completed 1 or more questionnaires. In total, 355 questionnaires were completed. The results indicated that CAI/RT did not impair physical, emotional, or social functioning. During and after CAI/RT, patients had significantly less pain (P = .02) and less nausea and vomiting (P = .01). Overall QoL (global functioning) tended to be better (P = .08) after CAI/RT.
Over a period of 24 months, CAI/RT improved QoL compared with observation alone in patients with resected pancreatic and periampullary cancer. This beneficial effect of CAI/RT was most prominent in the latter half of the follow-up.
据报道，辅助疗法对胰腺和壶腹周围癌的生存获益仅略有改善。在这项随机对照试验中，120 例接受胰十二指肠切除术的胰腺或壶腹周围癌患者接受了腹腔动脉输注化疗联合放疗（CAI/RT）或不接受辅助治疗。该研究的目的是比较 CAI/RT 组与未接受辅助治疗组患者的生活质量（QoL）。
在 CAI/RT 期间和之后，使用欧洲癌症研究和治疗组织（EORTC） QLQ-C30 问卷每 3 个月评估一次随机分组后 24 个月内的 QoL。
86%的患者（n=103）完成了 1 份或多份问卷。共完成了 355 份问卷。结果表明，CAI/RT 并未损害身体、情绪或社会功能。在 CAI/RT 期间和之后，患者的疼痛明显减轻（P=0.02），恶心和呕吐也明显减少（P=0.01）。CAI/RT 后总体 QoL（总体功能）往往更好（P=0.08）。
在 24 个月的随访期间，与单纯观察相比，CAI/RT 改善了接受胰十二指肠切除术的胰腺和壶腹周围癌患者的 QoL。CAI/RT 的这种有益作用在随访的后半段最为明显。
